SALT LAKE CITY, July 30, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will hold its fourth-quarter 2013 sales and earnings conference call with institutional investors and analysts at 4:30 p.m. ET on Tuesday, Aug. 13. During the call, Peter D. Meldrum, president and chief executive officer; James Evans, chief financial officer; and Mark Capone, president, Myriad Genetics will provide an overview of Myriad's financial performance for the quarter and full year.
To listen to the call, interested parties in the United States may dial 800-404-5245 or +1- 303-223-2688 for international callers. All callers will be asked to reference reservation number 21668391. The conference call also will be available through a live webcast at www.myriad.com . A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1-402-977-9140 for international callers, and entering reservation number 21668391.
About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .
CONTACT: Media Contact: Ron Rogers (801) 584-3065 email@example.com Investor Contact: Scott Gleason (801) 584-1143 firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts